Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions.

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Charles Schwab Investment Management Inc. raised its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free ...

Meeting to be held in New York on March 18 at 6 pm hosted by Truist. Light Up your Portfolio with Spark:Easily identify stocks' risks and ...

Arizona State Retirement System lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.8% in the ...

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at ...

Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Axsome Therapeutics' stock has risen 47% since my August recommendation, driven by FDA approvals and revenue growth, but I maintain a "sell" rating. Despite Auvelity's revenue growth, significant ...

As required by law, Axsome and Hikma will submit the settlement agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review. Similar patent litigation brought by ...

In this article, we are going to take a look at where Axsome Therapeutics, Inc. (NASDAQ:AXSM) stands against the other biotech stocks. No matter the market environment, you’ll always find ...

Axsome Therapeutics has entered into a settlement agreement with Hikma resolving patent litigation related to Axsome’s product Sunosi (solriamfetol). The litigation, which is pending in the ...